Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families

Breast Cancer Research

Heli Nevanlinna²  Carl Blomqvist¹  Kristiina Aittomäki³  Anitta Tamminen²  Päivi Heikkilä⁴  Hannaleena Eerola² 

[1] Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland;Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland;Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland;Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland

关键词: progesterone receptor;    p53;    hereditary;    oestrogen receptor;    breast cancer;   

Others  :  1115066
DOI  :  10.1186/bcr953

 received in 2004-06-15, accepted in 2004-09-30,  发布年份 2004

【 摘 要 】

Introduction

Histopathological features of BRCA1 and BRCA2 tumours have previously been characterised and compared with unselected breast tumours; however, familial non-BRCA1/2 tumours are less well known. The aim of this study was to characterise familial non-BRCA1/2 tumours and to evaluate routine immunohistochemical and pathological markers that could help us to further distinguish families carrying BRCA1/2 mutations from other breast cancer families.

Methods

Breast cancer tissue specimens (n = 262) from 25 BRCA1, 20 BRCA2 and 74 non-BRCA1/2 families were studied on a tumour tissue microarray. Immunohistochemical staining of oestrogen receptor (ER), progesterone receptor (PgR) and p53 as well as the histology and grade of these three groups were compared with each other and with the respective information on 862 unselected control patients from the archives of the Pathology Department of Helsinki University Central Hospital. Immunohistochemical staining of erbB2 was also performed among familial cases.

Results

BRCA1-associated cancers were diagnosed younger and were more ER-negative and PgR-negative, p53-positive and of higher grade than the other tumours. However, in multivariate analysis the independent factors compared with non-BRCA1/2 tumours were age, grade and PgR negativity. BRCA2 cases did not have such distinctive features compared with non-BRCA1/2 tumours or with unselected control tumours. Familial cases without BRCA1/2 mutations had tumours of lower grade than the other groups.

Conclusions

BRCA1 families differed from mutation-negative families by age, grade and PgR status, whereas ER status was not an independent marker.

【 授权许可】

   
2004 Eerola et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T: Clinicopathologic analysis of BRCA1- or BRCA2 associated hereditary breast carcinoma in Japanese women. Cancer 1999, 85:2200-2205.
• [2]Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod S, et al.: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000, 11:307-313.
• [3]Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998, 83:310-319.
• [4]Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton D: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318.
• [5]Eisinger F, Nogues C, Birnbaum D, Jacquemier J, Sobol H: BRCA1 and medullary breast cancer. JAMA 1998, 280:1227.
• [6]Phillips K, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 1999, 17:3653-3663.
• [7]Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affect the histoprognostic grade in hereditary breast cancer. Cancer Res 1996, 56:471-474.
• [8]Johannsson OT, Idvall I, Anderson C, Borg Å, Barkardottir RB, Egilsson V, Olsson H: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997, 33:362-371.
• [9]Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
• [10]Foulkes W, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
• [11]Marcus JN, Watson P, Page DL, Narod S, Lenoir G, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch H: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77:697-709.
• [12]Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998, 83:2335-2345.
• [13]Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomquist C, Kallioniemi OP, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2001, 93:152-154.
• [14]Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi O, et al.: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:539-548.
• [15]Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689.
• [16]Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi O, et al.: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997, 6:2309-2315.
• [17]Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter DJ, Freeman A, Antoniou AC, McGuffog L, et al.: The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000, 6:782-789.
• [18]Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodrigues S, Cigudosa JC, Diez O, Alonso C, et al.: Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003, 9:3606-3614.
• [19]Eerola H, Blomqvist C, Pukkala E, Pyrhönen S, Nevanlinna H: Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 2000, 36:1143-1148.
• [20]Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhönen S, Ponder BAJ, Muhonen T, Nevanlinna H: A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 1997, 60:1050-1058.
• [21]Huusko P, Pääkkönen K, Launonen V, Pöyhönen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J, et al.: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 1998, 62:1544-1548.
• [22]Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, et al.: Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000, 8:757-763.
• [23]Elston C, Ellis I: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
• [24]Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, et al.: A CHK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438.
• [25]Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, et al.: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997, 278:1242-1250.
• [26]Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997, 336:1409-1415.
• [27]Chan-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton MR, Royer-Pokora B: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet 1998, 35:116-121.
• [28]Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998, 62:145-158.
• [29]Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H: A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001, 84:704-708.
• [30]Gilpin CA, Carson N, Hunter AGW: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetic center. Clin Genet 2000, 58:299-308.
• [31]Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994, 12:888-894.
• [32]Ferno M, Borg A, Johansson U, Norgren A, Olsson H, Ryden S, Sellberg G: Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Acta Oncol 1990, 29:129-135.
• [33]Molino A, Pavarana M, Micciolo R, Nortilli R, Pedersini R, Manno P, Bozzo P, Bonetti F, Piubello Q, Cetto GL: Comparative study of clinical, pathological, and biological characteristics of symptomatc versus asymptomatic breast cancers. Ann Oncol 2000, 11:581-586.
• [34]Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR: Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002, 98:118-127.
• [35]Chu KC, Anderson WF, Fritz A, Ries LAG, Brawley OW: Frequency distributions of breast cancer chararacteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001, 92:37-45.